
Opinion|Videos|August 23, 2024
Management of Comment Adverse Effects Associated with mCRPC Therapies
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders explore strategies for managing common side effects associated with metastatic castration-resistant prostate cancer (mCRPC) treatments, including androgen receptor-targeted therapies.
Advertisement
Episodes in this series

How do you manage common side effects associated with mCRPC treatments, including androgen receptor-targeted therapies?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
2
Experts discuss the challenge of detecting CIS in bladder cancer
3
Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation
4
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
5













